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Adrenergic modulation of potassium metabolism in uremia. The effect
of chronic beta adrenergic blockade on potassium homeostasis during
moderate intensity exercise (40% of VO, max) was examined in seven
end-stage renal patients who were being maintained on chronic dialysis
treatment. Subjects participated in three study protocols: I) exercise
alone, 2) exercise plus propranolol (a nonselective beta-i, beta-2
antagonist), and 3) exercise plus metoprolol (a specific beta-I antago-
nist). The basal potassium concentration was similar in all three studies
and averaged 4.95 0.12 mEq/liter. During Study I (exercise alone),
plasma potassium rose by 0.26 0.09 mEq/liter. During exercise with
propranolol, plasma K concentration rose significantly higher ( plasma
K = 0.44 0.26mEq/liter; P < 0.05vs. exercise alone). In contrast, the
rise in plasma K during exercise with metoprolol ( plasma K = 0.20
0.08 mEq/liter) was similar to that observed with exercise alone.
Differences in potassium homeostasis between metoprolol and propran-
olol could not be explained by differences in hemodynamic parameters,
levels of potassium regulatory hormones, or acid base status. Thus, the
higher rise in potassium concentration during exercise with propranolol
could only be explained by adrenergic blockade at the beta-2 receptor
site. These results support the concept that adrenergic control of
extrarenal potassium homeostasis in dialysis patients is mediated at the
beta-2 receptor, Since a deterioration in potassium homeostasis during
exercise is observed with beta-2, but not beta-i blockade, selective
beta-i adrenergic blocking agents may be safer in dialysis patients.
Extrarenal tissues play a major role in the regulation of acute
potassium disposal [1]. During the first hours following potas-
sium administration in humans, more than 50% of an infused or
ingested potassium load is retained within the body and of the
retained potassium approximately 75 to 80% is translocated into
cells [1]. Several hormones, particularly insulin [2—4] and cate-
cholamines [5, 6], have been shown to modulate extrarenal
potassium homeostatasis.
Recent studies have shown that beta adrenergic stimulation
increases, while beta adrenergic inhibition decreases extrarenal
potassium tolerance [7, 8]. Furthermore, results from animal
studies indicate that the effect is mediated by the beta-2
adrenergic receptor [9]. These studies have potential clinical
importance concerning the use of beta adrenergic blocking
agents in the treatment of patients who are prone to develop
hyperkalemia, such as Type 1 diabetic individuals and uremic
subjects who are being maintained on chronic dialysis treatment
[10, ill. However, few studies have examined the effect of beta
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adrenergic blockade during physiologic conditions which are
likely to be associated with the development of hyperkalemia.
We recently have demonstrated that the serum potassium
concentration rises higher in Type I diabetic subjects during
exercise on chronic nonselective beta adrenergic blockade
(propranolol) compared to selective beta-i blockade (meto-
prolol) [10]. The present study was undertaken to examine this
phenomenon in dialysis patients. Physical exercise was chosen
as a physiological stimulus to induce hyperkalemia, since it is
likely to be a part of the patient's every day life and it is known
to induce a predictable and transient increase in plasma potas-
sium levels. Furthermore, many dialysis patients are encour-
aged to exercise to improve their sense of well being and their
functional capacity.
Methods
Subjects
Seven nondiabetic patients on maintenance dialysis treat-
ment (3 hemodialysis, 4 CAPD) volunteered to participate in the
study. There were three females and four males with a mean age
of 37 1 years (range 33 to 40 years). All subjects were within
20% of their ideal body weight, based on the medium frame
individuals of the Metropolitan Life Insurance Table, 1959.
Mean height and weight were 166 4 cm and 68 4 kg,
respectively. Serum urea nitrogen was 72 10 mg/dl (range 47
to 116) and serum creatinine was 16.1 1.0 mg/dl (range 9.5 to
20). No subject had any evidence of hepatic, cardiovascular,
endocrine, or other major organ system disease nor was there a
family history of diabetes in any subject. Except for vitamin
supplementation and phosphate binders, dialysis subjects con-
sumed no medications for at least seven days prior to their
participation in the study. For at least three days prior to the
study all subjects consumed a weight maintaining diet contain-
ing at least 200 grams of carbohydrate per day. None of the
uremic subjects was on a protein restricted diet. In the CAPD
subjects, all fluid was drained from the peritoneal cavity at 12
midnight on the evening prior to study. Dialysis was resumed as
usual after completion of the exercise protocol. In the hemodi-
alysis subjects, studies were performed the day following a
hemodialysis session. The purpose, nature and potential risks
of the study were explained to each subject before obtaining
his/her voluntary written consent. The experimental protocol
was reviewed and approved by the Human Investigation Com-
mittee of the Yale University School of Medicine.
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Experimental design
Each subject initially had his or her maximum aerobic capac-
ity determined on a bicycle ergometer. The mean V02 max
averaged 20 1 mllkg. mm (range 16 to 25). Subsequently, all
subjects participated in three separate study protocols, which
were performed at 8 a.m. after a 10 to 12 hour overnight fast. On
the morning of the study a small polyethylene catheter was
inserted into an antecubital vein before the start of exercise.
Blood samples were obtained without a tourniquet at 5 to 10
minute intervals in the basal period, and throughout the exer-
cise and recovery periods. Exercise was performed in the
sitting position on a bicycle ergometer. The intensity of exercise
was adjusted to represent 40% of each subjects V02 max.
Electrocardiographic tracings and blood pressure were moni-
tored throughout the basal, exercise and recovery period.
Study one: Exercise alone. After a thirty-minute basal period,
each subject exercised for forty minutes, and this was followed
by a thirty-minute recovery period.
Study two: Exercise plus chronic propranonol administra-
tion. Subjects received 40 mg of propranolol orally every 12
hours for three days prior to exercise. The last dose of propran-
olol was administered at 8 a.m. on the day of the study.
Exercise was performed as in study 1.
Study three: Exercise plus chronic metoprolol administra-
tion. Subjects received selective beta-i doses of metroprolol, 50
mg every 12 hours, for three days prior to exercise. The last
dose of metoprolol was administered at 8 a.m. on the day of the
study. Exercise was performed as in study 1.
The propranolol and metoprolol were administered in a
double blinded manner so that neither the subjects nor the
investigators knew which medication was being consumed. The
order of propranolol/metoprolol administration was randomized
and a washout period of two to three weeks was allowed
between the metoprolol and propranolol studies.
Analytical determinations
Plasma potassium concentration was determined by flame
photometry with lithium as an internal standard (Flame Pho-
tometer 443, Instrumentation Laboratory, Watertown, Massa-
chusetts, USA). Plasma insulin concentration was determined
by standard radioimmunoassay procedures [12]. Plasma gluca-
gon concentration was determined by radioimmunoassay using
the 30 K antibody of Unger [13]. Samples of epinephrine and
norepinephrrne were collected in glutathione and analyzed by a
radioenzymatic method (Cat-a-Kit, Upjohn, Kalamazoo, Mich-
igan, USA). Plasma aldosterone concentration was determined
by radioimmunoassay (Coat-a-Count, Diagnostic Product, Los
Angeles, California, USA) after chromatographic purification
according to the method of Buhler, Scaly and Laragh [14].
Bicarbonate concentration was determined on an acid base
analyzer (ABL 30, Radiometer, Copenhagen, Denmark).
Plasma glucose concentration was measured using the glucose
oxidase method (Glucose Oxidase Analyzer, Beckman Instru-
ments, Fullerton, California, USA).
Statistical analysis
All data are expressed as the mean SEM. Statistical
comparisons were performed using the two way analysis of
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Fig. 1. Time course of change in plasma potassium concentration in
dialysis subjects during exercise alone (open circles), exercise plus
propranolol (closed circles), and exercise plus metoprolol (closed
triangles). All values represent the mean SEM. < 0.05 vs. control
study. tP < 0.05 vs. metoprolol study.
variance with repeated measures and paired Student's t-test
analysis.
Results
Plasma potassium concentration
The basal plasma potassium concentration was similar in all
three studies and averaged 4.82 0.27, 4.99 0.27 and 4.89
0.27 mEq/liter in studies 1, 2, and 3, respectively. With the
onset of exercise alone there was a prompt rise in plasma
potassium concentration which reached a plateau value that
was 0.26 0.9 mEq/liter above baseline during the 30 to 40
minute time interval (Fig. 1). When exercise was stopped, the
plasma potassium concentration decreased to levels that were
0.20 to 0.25 mEq/liter below the basal value (Fig. 1).
After chronic propranolol administration, the increase in
plasma potassium concentration during both the exercise and
post-exercise recovery periods was approximately twice as
great as during the control study. During the 30 to 40 minute
time interval the mean increment in plasma potassium concen-
tration was 0.43 0.09 mEq/liter (P < 0.05 vs study 1). During
the 30 minute recovery period the plasma potassium also
remained higher (P < 0.05) than during the control study (Fig.
1).
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Table 1. Plasma hormone, glucose, and bicarbonate concentrations during the basal, exercise, and post exercise recovery periods during the
three experimental protocols
Basal
0
Exercise Recovery
70'20' 40'
Epinephrine pg/mi
Control 87 24 160 44l 75 20
Propranolol
Metoprolol
57 12
64 21
187 66b
188 27b
87 19
70 20
Norepinephrine pg/mi
Control 633 188 1043 280" 682 189
Propranolol
Metoprolol
782 159
771 245
1346 258"
1723 389
894 202
662 158
Insulin j&/ml
Control 17±3 17±3 16±2 16±2
Propranolol 22 5 22 5 25 4C 24 4C
Metoprolol 20 5 18 4 19 4 21 5
Glucagon pg/mi
Control 447 58 463 41 469 47 469 40
Propranolol 462 42 417 16 454 17 448 29
Metoprolol 472 93 449 52 434 43 450 66
Aldosterone mg/mi
Control 24 2 34 Y 46 7b 28 3
Propranolol
Metoprolol
22 3
38 5
39 4a
58 11"
52 1 1b
69 11"
33 6
50 llc(
Bicarbonate mEq/iiter
Control 22 2 21 2 20 2 21 2
Propranolol 20 2 20 2 19 2 20 2
Metoprolol 21 2 19 2 19 1 21 2
Glucose mg/di
Control 77 3 79 4 80 3 76 3
Propranolol 82 3 80 3 81 5 74 3
Metoprolol 83 2 85 4 82 4 78 3
All values represent the mean 5EM.
a P < 0.05 vs. basalb P < 0.01 vs. basal
P < 0.05 vs. control
d P < 0.05 vs. metoprolol
In contrast, when exercise was performed after chronic
metoprolol administration, the increment in plasma potassium
concentration during exercise was similar to that observed
during the control study and significantly lower (P < 0.05) than
when exercise was performed after propranolol administration
(Fig. 1). During the recovery period with metoprolol, plasma
potassium concentration did not fall significantly below basal
levels.
Plasma hormone, glucose, bicarbonate concentrations
The fasting plasma insulin concentration in the uremic pa-
tients was similar in the three studies and averaged 20 4
U/ml; no change in plasma insulin levels was observed during
the exercise and recovery periods in any of the three experi-
mental protocols (Table 1). The fasting plasma glucagon con-
centration was similar in the three studies and averaged 461
63 pg/mI; no significant change from baseline was observed in
any of the three experimental studies during the exercise or
recovery periods (Table 1). Basal catecholamine concentrations
were similar in all studies and rose approximately twofold
above baseline during exercise (P < 0.01; Table 1). During the
post-exercise recovery period both plasma epinephrine and
norepinephrine concentrations returned to basal levels. Basal
plasma aldosterone levels were similar in all three studies, rose
approximately twofold during all three exercise protocols (P <
0.01), and tended to return to baseline during the recovery
period (Table 1). The fasting plasma glucose concentrations
were similar in the three studies and averaged 81 3 mg/dl; no
change from baseline was observed during the exercise or
recovery periods (Table 1). Similarly, plasma bicarbonate levels
were nearly identical in each study and did not change signifi-
cantly during exercise. Further details concerning the metabolic
effects of exercise in these patient form the basis of a separate
report [15].
Blood pressure and heart rate
Exercise was associated with a significant increase in systolic
blood pressure and heart rate. When exercise was performed
with either propranolol or metoprolol, no increase in systolic
blood pressure was observed. Basal blood pressure was unaf-
fected by either chronic propranolol or metoprolol administra-
tion. The basal heart rate was significantly reduced by chronic
beta adrenergic blockade and the exercise-induced tachycardia
was blunted by both agents (Table 2).
Discussion
In the present study, the effect of chronic beta adrenergic
blockade on extrarenal potassium disposal in stable dialysis
patients was examined. The maintenance of chronic potassium
homeostasis is, in large part, regulated by the kidney [16]. In
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Table 2. Arterial blood pressure and heart rate during the basal state,
at the end of the 40 minute exercise period, and at the end of the 30
minute post-exercise recovery period
Basal Exercise Recovery
Control
Blood pressure Systolic 123 5 143 5b 123 5
mm Hg Diastolic 82 3 82 2b 81 1
Heart rate 74 2 126 3b 81 3
beats/mm
Propranolol
Blood pressure Systolic
Diastolic
120 5
78 5
125 58
78 5
112 671 5
Heart rate 63 3 99 6a,b 75 3
Metoprolol
Blood pressure Systolic
Diastolic
118 574 2 119 4870 38 118 370 3
Heart rate 63 38 90 58 72 4
All values represent the mean SEM.
ap < 0.05 vs. the control studyb P < 0.01 vs. basal
normal subjects more than 90% of the daily potassium intake is
excreted via the renal route [14]. In contrast, acute potassium
intake is dependent upon extrarenal mechanisms [1]. In patients
without significant renal function and urine output, it is obvious
that extrarenal tissues, liver and muscle [2], must play an even
more important role in potassium homeostasis if extremes of
hyperkalemia are to be prevented. This is a serious concern in
the clinical management of patients with end-stage renal disease
and represents one of the most common indications for the
initiation of dialysis treatment [17]. Several hormones, includ-
ing insulin, catecholamines and aldosterone, have been shown
to modulate extrarenal potassium homeostasis [1].
Rosa et al [5] and DeFronzo, Bia and Birkhead [6] were
amongst the first to demonstrate that, in humans, epinephrine
administration improves potassium tolerance during intrave-
nous potassium infusion. The potassium lowering effect of
epinephrine could not be explained by changes in renal potas-
sium excretion, and both groups concluded that epinephrine
improved potassium tolerance by increasing its extrarenal dis-
posal. Since the hypokalemic action of epinephrine could be
blocked by propranolol, the effect of the catecholamine on
extrarenal potassium tolerance was felt to be mediated via the
beta adrenergic receptor [5, 61. This conclusion is consistent
with in vitro studies in skeletal muscle [18]. Recent in vivo
studies employing an acutely nephrectomized rat model [9]
have shown that the protective effect of physiologic doses of
epinephrine on potassium tolerance following potassium infu-
sion could by mimicked by the administration of a selective
beta-2 but not by a beta-l agonist. Conversely, both non-
selective beta-i, beta-2 and selective beta-2 antagonists caused
a deterioration in extrarenal potassium tolerance Selective
beta-i blocking agents, such as metoprolol, did not affect
extrarenal potassium tolerance. These results confirm previous
findings and indicate that the beta-2 adrenergic receptor plays a
primary role in extrarenal potassium disposal. With respect to
this [19], recent reports have demonstrated that nebulized
albuterol, a selective beta-2 agonist, causes a significant and
dose dependent decline in plasma potassium concentration in
hemodialysis patients [201. This provides a reasonable alterna-
tive for the acute treatment of serious hyperkalemia in this
patient population. These observations have important clinical
implications for patients with impaired potassium homeostatic
mechanisms, such as diabetic and dialysis subjects, who often
are treated with beta adrenergic blocking agents.
A few preliminary studies have suggested that the plasma
potassium concentration may be higher in dialysis patients on
propranolol [ii]. However, few studies have attempted to
assess whether the beta adrenergic nervous system plays a
regulatory role in potassium homeostasis under physiologic
conditions, such as stress and exercise, which may be encoun-
tered in every day life. Aerobic physical exercise is associated
with a significant rise in the plasma potassium concentration,
the magnitude of which is related to the work load and the
duration of physical activity. The regulation of extrarenal
potassium homeostasis is multifactorial, with the beta-2 recep-
tor playing an important role in the transfer of potassium across
the cell membrane [1, 5, 7], while the beta-i receptor appears to
regulate blood flow to muscle and liver [21, 22], the two tissues
primarily responsible for extrarenal potassium uptake. Because
both beta-i and beta-2 receptors are involved in the regulation
of potassium metabolism and because the sensitivity of each of
these receptors can be regulated (either negatively or posi-
tively) by any of the myriad of metabolic/endocrine/cardiovas-
cular/neurogenic derangements that occur in uremia, we felt
that it was important to examine the effect of beta-adrenergic
blockade on potassium homeostasis in dialysis patients whose
only mechanism of potassium disposal is via the extrarenal
route. In healthy young adults it has been shown that both
selective and non-selective beta blockade impair potassium
homeostasis during moderate aerobic exercise, although the
impairment was less severe with beta-i blockade and primarily
involved the post-exercise recovery period. These observations
are consistent with the concept that the beta-2 receptor is
primarily involved with cellular potassium transfer, whereas the
beta-i receptor regulates blood flow to tissues that govern
potassium uptake.
In the present study we have examined the effect of selective
(metoprolol) and nonselective (propranolol) beta adrenergic
antagonists on the exercise-induced rise in plasma potassium
concentration in end-stage renal failure patients who were being
maintained on chronic dialysis. Since urine output was absent
or negligible in all subjects, any differences in the plasma
potassium concentration between the control and experimental
studies must be due to an impairment in extrarenal potassium
metabolism. As can be seen in Figure 1, three days of propran-
olol administration was associated with a twofold greater incre-
ment in the plasma potassium concentration compared to the
control study. In contrast, metoprolol caused no deterioration
in potassium tolerance during the exercise period, although the
plasma potassium concentration failed to decline below basal
levels during the post-exercise recovery period. These results
are different from those previously reported by us [10] as well as
by others [23] in healthy young subjects in whom metoprolol
significantly affected the post-exercise decline in plasma potas-
sium concentration. These findings suggest a diminished impact
of beta-i-mediated cardiovascular adaptations with an increase
in muscle/liver blood flow.
However, before concluding that the deleterious effect of
propranolol is mediated by a beta-mediated phenomenon, it is
important to consider other factors that are known to affect
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extrarenal potassium metabolism. Small increases in the plasma
insulin concentration (20 to 40 iU/ml) have been shown to
enhance both splanchnic and peripheral (muscle and adipocyte)
potassium uptake [2]. Conversely, a decline in insulin concen-
tration below basal levels impairs potassium tolerance [3]. In
normal subjects a decline in insulin levels during exercise is
usually observed, and this may contribute to the observed rise
in plasma potassium concentration. However, in the present
study there was no significant change in the plasma insulin
concentration during either the exercise or post-exercise recov-
ery period in any of the three experimental protocols. Thus, it
is unlikely that alterations in insulin metabolism play any role in
the impaired potassium tolerance observed following propran-
olol administration.
Circulating catecholamine levels also can affect extrarenal
potassium metabolism [5, 6J. Since the plasma epinephrine and
nonepinephrine concentrations rose to the same extent during
the control study and during tue two studies performed with
beta adrenergic blockade, it is unlikely that either hormone can
explain the deterioration in potassium tolerance observed with
propranolol. Plasma aldosterone levels also rose in response to
exercise. This was not unexpected since both potassium and
cathecolamines stimulate aldosterone secretion [24]. Although
aldosterone can affect extrarenal potassium tolerance [25], no
differences in the plasma aldosterone concentrations between
any of the three studies were observed. It also is unlikely that
changes in acid base balance can explain the excessive rise in
plasma potassium concentration following propranolol since the
venous bicarbonate concentration remained constant in all
three experimental protocols during both exercise and recovery
periods. Lastly, since propranolol and metoprolol blocked the
exercise induced rise in blood pressure and pulse to the same
extent, it is unlikely that a difference in hemodynamics can
explain the differing results during exercise between these
agents. We can, therefore, reasonably conclude that the dete-
rioration in potassium homeostasis with propranolol adminis-
tration can be ascribed to beta-2 adrenergic blockade.
During recovery there was a fall in plasma potassium con-
centration of approximately 0.3 mEq/liter below baseline in the
control study; this decline was similar to that previously re-
ported by us in normal subjects [10] and most likely related to
the persistently elevated levels of epinephrine. This fall below
baseline was not observed with either beta blocking agents and
is consistent with a beta-i blockade induced decrease in blood
flow to muscle and liver in the recovery period. The mild
decrease in blood pressure and pulse during the recovery period
with beta blockade compared to the control study supports this
interpretation.
In conclusion, nonspecific beta adrenergic blockade with
propranolol causes a deterioration in extrarenal potassium
metabolism during exercise in stable dialysis patients. In con-
trast, metoprolol, a specific beta-I adrenergic antagoinst, does
not impair extrarenal potassium homeostasis. Exercise is fre-
quently encouraged in dialysis patients since a number of
studies have demonstrated that it can dramatically improve
functional capacity in these patients [26, 27]. The current
results suggest that, in dialysis patients who must be started on
a beta blocking agent, selective beta-l adrenergic blocking
agents may be a safer choice.
Reprint requests to Ralph A. DeFronzo, M.D., Diabetes Division,
University of Texas Health Science Center at San Antonio, 7703 Floyd
Curl Drive, San Antonio, Texas 78284, USA.
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